220 - Pioneering Drug Development for Hearing Loss with Dr. Jonathan Kil episode artwork

EPISODE · Jul 8, 2024 · 35 MIN

220 - Pioneering Drug Development for Hearing Loss with Dr. Jonathan Kil

from This Week in Hearing · host This Week in Hearing

In this episode, we welcome Dr. Jonathan Kil, the CEO and CMO of Sound Pharmaceuticals to discuss the latest developments in hearing loss treatment. With a distinguished background in auditory neuroscience and otolaryngology, Dr. Kil co-founded Sound Pharmaceuticals over 22 years ago with a mission to develop drug-based therapies for sensorineural hearing loss and tinnitus. He has led the company’s research and development strategy, securing numerous NIH and Department of Defense awards, and spearheading numerous clinical studies. Dr. Kil recounts the journey of Sound Pharmaceuticals over the past two decades, highlighting the challenges faced and milestones achieved. He focuses on the development of SPI-1005. SPI-1005 is an investigational drug that contains ebselen, a small molecule that is a new chemical entity, under FDA classification, an innovative drug currently in clinical trials for Meniere's disease, noise-induced hearing loss, and aminoglycoside ototoxicity. Dr. Kil emphasizes the importance of their work, explaining how these treatments aim to provide better solutions for patients and improve their quality of life. Dr. Kil recounts the journey of Sound Pharmaceuticals over the past two decades, highlighting the challenges faced and milestones achieved. He focuses on the development of SPI-1005, an investigational drug containing ebselen, a novel anti-inflammatory compound that mimics and induces the activity of Glutathione Peroxidase, an enzyme critical to hearing and balance. Currently in clinical trials, SPI-1005 has shown safety and efficacy in treating three different forms of acquired sensorineural hearing loss in adults: loud sound exposure or acute noise-induced hearing loss, Meniere's disease, and antibiotic-induced ototoxicity. Dr. Kil explains the science behind these innovative therapies, the potential impact they may have, and the rigorous steps being taken to bring them to market. The conversation provides a unique perspective on the current state and future of pharmaceutical treatments for hearing loss and other inner ear conditions. Learn more about Sound Pharmaceuticals here: https://soundpharma.com Be sure to subscribe to our YouTube channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and X (formerly Twitter): https://www.linkedin.com/company/this-week-in-hearing/ https://twitter.com/WeekinHearing

Episode metadata supplied by the publisher feed · Published Jul 8, 2024

Embed this episode

NOW PLAYING

220 - Pioneering Drug Development for Hearing Loss with Dr. Jonathan Kil

0:00 35:02

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of This Week in Hearing?

This episode is 35 minutes long.

When was this This Week in Hearing episode published?

This episode was published on July 8, 2024.

Can I download this This Week in Hearing episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!